Navigation Links
Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
Date:6/9/2009

Launch represents first available generic equivalent of Alkeran(R)

LAKE FOREST, Ill., and NEWTOWN, Pa., June 9 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC, announced today the FDA approval and launch of Melphalan Hydrochloride for Injection, the generic equivalent of Alkeran(R) from GlaxoSmithKline.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

Bioniche Pharma and Synerx Pharma entered into a definitive agreement whereby Synerx developed and secured the U.S. Food and Drug Administration's approval of Melphalan and Bioniche Pharma has the exclusive rights to market and distribute Melphalan in the United States.

"The launch of Melphalan represents Bioniche's introduction to the generic injectable oncology market and underscores our commitment to rapid and aggressive product line growth," said George Zorich, President, US Operations for Bioniche Pharma. "We are pleased to have partnered with Synerx and value their expertise in developing this specialty generic product to meet the needs of cancer patients."

Bioniche Pharma will commence shipment of Melphalan Hydrochloride for Injection immediately in cartons with one single-use vial containing melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL vial of sterile diluent.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at www.bionichepharma.com.

About Synerx Pharma:

Synerx Pharma, LLC is a privately help corporation located in historic Bucks County Pennsylvania. Established in January 2004, the company develops and brings to market select pharmaceutical products aimed at addressing unmet market needs, particularly those involving some combination of barriers to entry. The company focuses on developing cost effective specialty generic pharmaceuticals and small brand products. Synerx presently has five FDA approved products, and a development portfolio of ten projects at various stages of development in multiple dosage forms. More information can be found at www.synerxpharma.com

Alkeran(R) is a registered trademark of GlaxoSmithKline.


'/>"/>
SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Represented at House of Commons Sub-Committee on Food Safety
2. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
3. Bioniche Reports Fiscal 2009 Third Quarter
4. Bioniche Provides a Corporate Update
5. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
6. Bioniche Revolving Credit Facility Maturity Date Amended
7. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
8. Bioniche Warrants Expiration Date to be Extended
9. Bioniche Reports Fiscal 2009 Second Quarter
10. Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable
11. Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... Tanya Atagi, MD, is excited to announce ... Atagi Plastic Surgery and Skin Aesthetics. , To tighten skin on the face, ... ultrasound energy. Smoother, younger-looking skin is revealed on all other areas of the body ...
(Date:8/17/2017)... CO (PRWEB) , ... August 17, 2017 , ... ... Moral Injury: The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, ... (war) trauma, to encourage inner healing of memories and achieve forgiveness, through a ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Pot Valet is ... service growing to every city in the state, and soon, every state in the ... their need to visit a cannabis dispensary altogether. , According to Pot ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Centrifugation is more ... in the laboratory that we can no longer do without. And just like a ... of your device. , In this webinar, attendees will learn about the most important ...
(Date:8/17/2017)... Seattle, WA and Lighthouse Point, FL (PRWEB) , ... ... ... Seattle-based healthcare technology firm and Cancer Center Business Development Group, a Florida-based oncology ... that examined patient care data to quantify the dollar amount of attributable savings ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... LOVELAND, Colo. , July 26, 2017 ... Tristan Guttridge and the Bimini SharkLab to custom design the ... diagnostic images of sharks in their native habitat. In ... for Discovery Channel,s Shark Week, Dr. Guttridge approached ... to take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 /PRNewswire/ ... drugs to treat rare nervous system diseases, has concluded a ... and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before ... promising results in a Phase 2 study conducted in ... in the United States ...
Breaking Medicine Technology: